Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2013-12-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
第五届董事会第二十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of 普洛药业股份有限公司 (Puloyao Pharmaceutical Co., Ltd.). It details the approval of several proposals including the establishment of a subsidiary, capital increase in a holding subsidiary, and signing of a share transfer framework agreement. The document includes voting results and confirms the legality and validity of the meeting. There is no indication that this is a full report or financial statement, nor is it a shareholder meeting announcement or voting result declaration. It is clearly a Board/Management Information announcement regarding board decisions and management actions.
2013-12-19 Chinese
第五届监事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 普洛药业股份有限公司 regarding decisions made in their 16th meeting of the 5th session. It includes voting results on corporate matters such as establishing a subsidiary, capital increase, and signing a share transfer agreement. There is no financial data, no mention of annual or interim reports, no earnings data, and no regulatory certifications. The document is a formal announcement of board/management decisions rather than a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2013-12-19 Chinese
关于公司对控股子公司追加注册资本的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding an increase in registered capital of its controlling subsidiary 上海普洛康裕药物研究院有限公司. It details the capital injection amounts, shareholding percentages before and after the transaction, and states that the matter does not require shareholder meeting approval. The document is short (1313 characters) and focuses on a capital increase transaction rather than a full financial report or detailed analysis. There is no financial statement or comprehensive report content. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising or capital structure changes.
2013-12-19 Chinese
详式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled '详式权益变动报告书' which translates to 'Detailed Equity Change Report'. It is issued by 横店集团控股有限公司 (Hengdian Group Holdings Co., Ltd.) regarding its equity interest in 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.). The document includes detailed sections about the equity change, the information disclosure obligations, the controlling shareholders, the purpose of the equity change, the method of equity change, funding sources, and other related information. It also references relevant Chinese laws and regulations governing equity changes and disclosures. The content is focused on a significant change in shareholding and equity interests, consistent with a Major Shareholding Notification. The document is lengthy (15,000 characters) and contains substantive information about the equity change, not merely an announcement or a certification. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ).
2013-12-10 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details a change in shareholding by Zhejiang Guangtai Industrial Development Co., Ltd., including the reduction of shares held in Puluo Pharmaceutical Co., Ltd. It includes specifics about the share transfer agreement, shareholding percentages before and after the transaction, and legal compliance statements. The document is focused on reporting a change in major shareholding stakes, with no financial statements or earnings data. It is not an annual or interim report, nor an earnings release or management discussion. It fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length (9805 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2013-12-10 Chinese
关于控股股东股权结构变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in the equity structure of the controlling shareholder of the company 普洛药业股份有限公司. It details the transfer of shares between entities related to the controlling shareholder and the resulting shareholding percentages before and after the transaction. There is no indication of financial statements, audit information, or meeting materials. The document is a formal announcement of a change in major shareholding structure, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming it is not a full report or other type of filing.
2013-12-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.